PerkinElmer
check quantity

PAI-1 (human) LANCE Ultra TR-FRET Detection Kit, 10,000 Assay Points

The LANCE® Ultra Human PAI-1 Detection Kit is designed for detection and quantitation of human PAI-1 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

You successfully added item(s) to your cart

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
TRF1286C
500 Assay Points
796.00 USD
more
TRF1286M
10,000 Assay Points
10600.00 USD
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

The LANCE® Ultra Human PAI-1 Detection Kit is designed for detection and quantitation of human PAI-1 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.



  • No-wash steps, no separation steps

  • TR-FRET technology

  • Sensitive detection

  • High reproducibility

  • Faster time-to-results

  • Easy automation

  • 96-well, 384-well, and 1536-well formats


LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.


Plasminogen activator inhibitor-1 (PAI-1) is a single chain glycoprotein of 50 kDa. PAI-1 is secreted and is mainly produced by the endothelium, liver, and adipose tissue. It is also produced by certain tumours. PAI-1 activity is tightly regulated on the transcriptional level by transforming growth factor β. PAI-1 is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA), which convert plasminogen to plasmin. Congenital PAI-1 deficiency can cause hemorrhagic diathesis. PAI-1 is present in larger amounts in various pathologies, such as in a number of cancers or obesity. In breast cancer, high levels of PAI-1 are associated with a high risk of recurrence.

Specifications

Assay Target PAI-1
Assay Target Class Protein
Automation Compatible Yes
Detection Method Time-Resolved Fluorescence (TRF), TR-FRET
Experimental Type In vitro
Shipping Condition Blue Ice
Target Species Human
Therapeutic Area Cancer
Unit Size 10,000 Assay Points